Beyond Chemotherapy: Current and Future Molecular-Targeted Therapy in Ovarian Cancer, Oncology, Treatment Updates, Ovarian Cancer 2009, Clinical Care Options.com.
- The Need for Molecular-Targeted Therapy, Michael V. Seiden, MD, PhD, reviews the role of molecular-targeted therapy in ovarian cancer. [Microsoft PowerPoint required to view slides].
- VEGF Targeted Therapy in Ovarian Cancer: Basis & Directions, Robert A. Burger, MD, discusses the rationale for using VEGF inhibitors in ovarian cancer and reviews current phase II and III trials evaluating these agents in the frontline and recurrent setting. [Microsoft PowerPoint required to view slides].
- Targeting EGF and Other Signal Transduction Pathway, Thomas J. Herzog, MD, discusses targeting EGF and other approaches such as Src inhibition, c-Met inhibition, PARP inhibition, and mTOR inhibition as therapy for ovarian cancer. [Microsoft PowerPoint required to view slides]
- Immunologic-Targeted Therapy in Ovarian Cancer, George Coukos, MD, PhD, discusses immunologic-targeted therapy as a therapeutic strategy for ovarian cancer. [Microsoft PowerPoint required to view slides]
“Novel Therapies for Ovarian Cancer,” Presentation by Christina S. Chu, M.D., New York University (NYU) Medical Center, New York, NY – Oct 20th, 2007, sponsored by Gynecologic Cancer Foundation, Fora.tv (40 minute video).
“Biological Therapies for Cancer: Questions and Answers,” National Cancer Institute Fact Sheet, June 13, 2006.
“Biological Therapy: Treatments That Use Your Immune System to Fight Cancer, National Cancer Institute,”National Cancer Institute, January 14, 2004.
Targeted Therapy Tutorial, National Cancer Institute, June 2, 2009 (This animated tutorial for health professionals provides an overview of an emerging approach to cancer treatment called targeted therapies. The tutorial includes representative examples of the main types of targeted therapies and describes their mechanisms of action. It also explains how advanced research techniques, such as whole-genome profiling, contribute to the development of targeted therapies).
“Targeted Cancer Therapies: Questions and Answers,” National Cancer Institute Fact Sheet, June 13, 2006.
Cytokine & Interleukin Therapy:
“Cytokines and Cancer Therapy,” by Jeffrey Weber, M.D. Ph.D., Meds.com
“Nonspecific Immunotherapies and Adjuvants,” American Cancer Society, March 18, 2008.
“Outpatient Treatment with Interleukin-2 (IL-2),” Clinical Center, National Institutes of Health,
“Immunotherapy For Cancer,” A Continuing Medical Education Enduring Materials, by Howard Kaufman, M.D., FACS, et. al., Meds.com, August 2003.
“Immunotherapy,” American Cancer Society, March 18, 2008.
“Cancer Immunotherapy: Harnessing the Immune System to Help the Body Fight Cancer,” Center News, Memorial Sloan-Kettering Cancer Center, April 2007.
“Cancer Immunology,” Cancer Research Institute, 2008.
“Immunotherapy,” The Merck Manual, August 2007.
“Immunotherapy: Stimulating the Immune System to Prevent or Treat Cancer (including How Does Immunotherapy Work? Video),” Mayo Clinic.
“Cancer immunotherapy: Combining approaches to achieve checkmate,” by Lonnie Christiansen, Dana-Farber/Harvard Cancer Center News
“Immunotherapy For Specific Cancers,” American Cancer Society, March 18, 2008.
“Cancer Immunology and Immunology Research Program (incl. Using the Immune System To Treat Cancer Video),” Standford Cancer Center.
“ Immunotherapy: Looking through cancer’s invisibility cloak,” by Karen Mittelstedt, FirstScience.com, January 13, 2008.
“Immunologic Approaches to Ovarian Cancer Treatment,” Paul Sabbatini (Memorial Sloan-Kettering Cancer Center), Kunle Odunsi (Roswell Park Cancer Institute), Journal of Clinical Oncology, Vol 25, No 20 (July 10), 2007: pp. 2884-2893.
“Shedding Light on Immunotherapy for Cancer,” Steven A. Rosenberg, M.D., Ph.D., New England Journal of Medicine, Volume 350:No.14:1461-1463 (April 1, 2004)
“Immunotherapy, Biologic Therapy, and Biotherapy,” Ovarian-News.org, June 15, 2005.
“Cancer Vaccines,” American Cancer Society, March 18, 2008.
“Tumor Immunology,” by Mary L. Disis, M.D., Meds.com.
“Vaccines Targeting Breast and Ovarian Cancer,” 2006 Science Forum, University of Washington (Mary L. Disis, M.D. presentation regarding cancer vaccines), Research Channel YouTube Video, posted March 10, 2008.
“Vaccine Approaches Against Cancer,” by Michael A. Morse, M.D., Meds.com
“Vaccine-and-antibody treatment shows effectiveness and milder side effects in advanced melanoma and ovarian cancer patients,” Dana-Farber Cancer Institute Press Release, February 19, 2008.
“Avax Technologies Announces Initiation of Clinical Study With Autologous Ovarian Cancer Vaccine,” posted by Paul Cacciatore, H*O*P*E* Blog, April 10, 2008.
“Five Years Later, Patient Participating in Vaccine Trial Remains Free of Ovarian Cancer,” posted by Paul Cacciatore, H*O*P*E* Blog, April 7, 2008.
“Cancer Vaccines – Exploring New Approaches to Treatment,” The Wellness Community.
“Vaccines for Ovarian and Breast Cancer in Early Trials,” by Steven Reinberg, MedicineNet.com News, January 11, 2008 [Article Source: George Coukos, M.D., Ph.D., assistant professor of obstetrics and gynecology, University of Pennsylvania, Philadelphia; Leisha A. Emens, M.D., Ph.D., assistant professor of oncology, Johns Hopkins University, Baltimore; Jan. 10, 2008, presentation, Alliance for Cancer Gene Therapy, Greenwich, Conn.]
“Ovarian Cancer Vaccine Might Extend Survival,” by Amanda Gardner, MedicineNet.com, July 23, 2007 (article cites the study entitled, “Vaccination with an NY-ESO-1 peptide of HLA class I/II Specificities Induces Integral Humoral and T Cell Responses In Ovarian Cancer,” Kunle Odunsi et. al., Proceedings of the National Academy of Sciences, Vol. 104:no. 31( July 31, 2007) pp.12837-12842)(PDF Document Download).
“RPCI Receives Three-Year Grant to Develop Ovarian Cancer Vaccine,” Roswell Park Cancer Institute Press Release, March 14, 2008.
“LICR Melanoma & Ovarian Cancer Initiatives Meeting Report,” Ludwig Institute For Cancer Research, September 2007.
Monoclonal Antibodies (including Anti-HER2) Therapy:
“Monoclonal Antibodies,” American Cancer Society, March 18, 2008.
“HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients,” Marianne Tuefferd et. al., PLoS ONE 2(11): e1138. doi:10.1371/journal.pone.0001138 (Nov. 2007) (PDF Document Download).
“Herceptin® (Trastuzumab): Questions and Answers,” National Cancer Institute Fact Sheet, June 13, 2006.
“HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Posible Novel Treatment Modality Using Recombinant Monoclonal Antibody Against HER2, Trastuzumab:,” Masaki Fujimura et. al., Jpn. J. Cancer Res. 93, 1250-1257, November 2002.
Angiogenesis Inhibitors Therapy: Questions and Answers, National Cancer Institute Fact Sheet, May 27, 2008.
“Understanding Cancer Series: Angiogenesis,” National Cancer Institute, September 1, 2006.
“Anti-Angiogenesis: A New Frontier in Cancer,” Genetech and Coalition of Cancer Cooperative Groups, NewFrontierInCancer.org.
“Anti-Angiogenesis Drugs – What Are These Therapies and How Do They Work?, by Rakesh K. Jain, PhD, professor of tumor biology at Harvard Medical School in Boston, and the director of the Steele Laboratory of Tumor Biology at Massachusetts General Hospital, American Association of Cancer Research, June 25, 2007.
“Bevacizumab (AvastinTM) for Treatment of Solid Tumors: Questions and Answers,” National Cancer Institute Fact Sheet, August 3, 2005.
“Novel Medication [bevacizumab] Improves Ovarian Cancer Treatment,” Science News, ScienceDaily, November 1, 2007.
Results Obtained From Search of ClinicalTrials.gov with the Phrase “ovarian cancer and bevacizumab.”
“Angiogenesis Inhibitors in Clinical Trials,” National Cancer Institute, August 13, 2007.
Targeting Cancer With Small Molecule Kinase Inhibitors, J Zhang; PL Yang; NS. Gray, Nat Rev Cancer. 2009;9(1):28-39 (reprint online at Medscape Today on 13 Feb. 2009) (free Medscape Today subscription required to view article).